Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

2.1K
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
2.1K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.5K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.5K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.0K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medial prefrontal cortex and ventrolateral orbitofrontal cortex inputs into the ventrolateral periaqueductal grey region differentially regulate pain and anxiety like behavior.

Neuroscience·2026
Same author

Gating effects of a Cav2.3 calcium channel variant linked to developmental and epileptic encephalopathy.

Neuroscience·2026
Same author

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same author

Practical and divergent electrochemical access to thiocarbamoyl fluorides and N-trifluoromethyl amines from secondary amines.

Nature communications·2026
Same author

Electrochemical Trideuteromethylation with AcOD-<i>d</i><sub>4</sub>: A Route to CD<sub>3</sub>-Labeled Building Blocks.

Organic letters·2026
Same author

Probing 3-Amino-2H-Azaindazoles as Allosteric Inhibitors of the Protein Tyrosine Phosphatase SHP2.

ChemMedChem·2026
Same journal

Design-Expert Assisted Formulation Development, Optimization, and Evaluation of Selegiline and Biochanin A Loaded Self-Nanoemulsifying Drug Delivery System.

Drug development research·2026
Same journal

Contrastive Learning-Powered Ultrafast Genome-Wide Virtual Screening: The Rise of DrugCLIP.

Drug development research·2026
Same journal

Design, Synthesis, and Biological Evaluation of Chiral Urea and Thiourea Derivatives as Multitarget-Directed Anti-Alzheimer Agents.

Drug development research·2026
Same journal

Benzimidazole-Based VEGFR-2 Inhibitors Inspired by Sorafenib: Synthesis, Biological Evaluation, and Mechanistic Insights.

Drug development research·2026
Same journal

Luliconazole Potentiates Efficacy of Miltefosine Against Leishmania donovani.

Drug development research·2026
Same journal

Naphthalene-4H-Chromene Molecular Hybrids as Dual Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease.

Drug development research·2026
See all related articles

Related Experiment Video

Updated: Mar 17, 2026

One-channel Cell-attached Patch-clamp Recording
13:07

One-channel Cell-attached Patch-clamp Recording

Published on: June 9, 2014

25.6K

Hexahydroquinoline Featuring Amide Functionality: A Promising Scaffold With Calcium Channel Blocking Activity.

Ebru Koçak Aslan1, Kevin Lam2, Sun Huang3

  • 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.

Drug Development Research
|March 15, 2026
PubMed
Summary
This summary is machine-generated.

New hexahydroquinoline (HHQ) amides show potential as calcium channel blockers for cardiovascular and pain conditions, offering improved metabolic stability over traditional ester-based drugs.

Keywords:
Hantzsch synthesisdihydropyridineenantioseparationmetabolic stabilitymolecular modelingpatch clamp

More Related Videos

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

9.0K
Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

6.7K

Related Experiment Videos

Last Updated: Mar 17, 2026

One-channel Cell-attached Patch-clamp Recording
13:07

One-channel Cell-attached Patch-clamp Recording

Published on: June 9, 2014

25.6K
Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

9.0K
Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

6.7K

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Cardiovascular Research

Background:

  • Hexahydroquinoline (HHQ) derivatives are recognized for diverse pharmacological activities.
  • 1,4-dihydropyridine (DHP) is the core pharmacophore for calcium channel blockers, crucial in managing cardiovascular diseases and pain.
  • Current DHPs utilize ester functionality; exploring bioisosteric amide replacements is key for novel therapeutics.

Purpose of the Study:

  • To synthesize novel HHQ compounds with ester or amide functionalities (EM1-EM15).
  • To investigate the effects of these compounds on L-type (Cav1.2) and T-type (Cav3.2) calcium channels.
  • To evaluate the potential of amide-containing HHQs as next-generation calcium channel blockers.

Main Methods:

  • Synthesis of novel HHQ ester and amide derivatives (EM1-EM15).
  • Whole-cell patch clamp electrophysiology to assess calcium channel blocking activity.
  • Molecular docking and dynamics simulations for binding mode analysis.
  • In vitro metabolic stability assays using rat microsomes.

Main Results:

  • Amide-containing HHQs demonstrated significant blocking activity on both L-type and T-type calcium channels, though less potent than ester counterparts.
  • The (R)-enantiomer of EM4 was identified as the primary contributor to calcium channel blockade.
  • Molecular simulations revealed binding modes in Cav1.2 similar to amlodipine and identified a binding site in Cav3.2.
  • Amide derivatives exhibited superior metabolic stability compared to esters.

Conclusions:

  • Hexahydroquinoline scaffolds with amide groups represent a promising avenue for developing novel calcium channel blockers.
  • These compounds show potential for treating cardiovascular diseases and pain, with enhanced metabolic stability.
  • The (R)-isomer is crucial for the observed calcium channel blocking activity.